Skip to main content
Top
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Low-cost HPV testing and the prevalence of cervical infection in asymptomatic populations in Guatemala

Authors: Hong Lou, Eduardo Gharzouzi, Sarita Polo Guerra, Joël Fokom Domgue, Julie Sawitzke, Guillermo Villagran, Lisa Garland, Joseph F. Boland, Sarah Wagner, Héctor Rosas, Jami Troxler, Heidi McMillen, Bailey Kessing, Enrique Alvirez, Miriam Castillo, Hesler Morales, Victor Argueta, Andert Rosingh, Femke J. H. B. van Aerde-van Nunen, Griselda Lopez, Herbert M. Pinedo, Mark Schiffman, Michael Dean, Roberto Orozco

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

A low cost and accurate method for detecting high-risk (HR) human papillomavirus (HPV) is important to permit HPV testing for cervical cancer prevention. We used a commercially available HPV method (H13, Hybribio) which was documented to function accurately in a reduced volume of cervical specimen to determine the most prevalent HPV types and the distribution of HPV infections in over 1795 cancer-free women in Guatemala undergoing primary screening for cervical cancer by cytology.

Methods

HR-HPV detection was attempted in cervical samples from 1795 cancer-free women receiving Pap smears using the Hybribio™ real-time PCR assay of 13 HR types. The test includes a globin gene internal control. HPV positive samples were sequenced to determine viral type. Age-specific prevalence of HPV was also assessed in the study population.

Results

A total of 13% (226/1717) of women tested HPV+, with 78 samples (4.3%) failing to amplify the internal control. The highest prevalence was found in younger women (< 30 years, 22%) and older ones (≥60 years, 15%). The six most common HR-HPV types among the 148 HPV+ typed were HPV16 (22%), HPV18 (11%), HPV39 (11%), HPV58 (10%), HPV52 (8%), and HPV45 (8%).

Conclusions

In this sample of cancer free women in Guatemala, HPV16 was the most prevalent HR type in Guatemala and the age-specific prevalence curve peaked in younger ages. Women in the 30-59-year age groups had a prevalence of HR-HPV of 8%, however, larger studies to better describe the epidemiology of HPV in Guatemala are needed.
Appendix
Available only for authorised users
Literature
1.
go back to reference Valles X, Murga GB, Hernandez G, Sabido M, Chuy A, Lloveras B, Alameda F, de San Jose S, Bosch FX, Pedroza I, et al. High prevalence of human papillomavirus infection in the female population of Guatemala. Int J Cancer. 2009;125(5):1161–7.CrossRef Valles X, Murga GB, Hernandez G, Sabido M, Chuy A, Lloveras B, Alameda F, de San Jose S, Bosch FX, Pedroza I, et al. High prevalence of human papillomavirus infection in the female population of Guatemala. Int J Cancer. 2009;125(5):1161–7.CrossRef
2.
go back to reference Ngelangel C, Munoz N, Bosch FX, Limson GM, Festin MR, Deacon J, Jacobs MV, Santamaria M, Meijer CJ, Walboomers JM. Causes of cervical cancer in the Philippines: a case-control study. J Natl Cancer Inst. 1998;90(1):43–9.CrossRef Ngelangel C, Munoz N, Bosch FX, Limson GM, Festin MR, Deacon J, Jacobs MV, Santamaria M, Meijer CJ, Walboomers JM. Causes of cervical cancer in the Philippines: a case-control study. J Natl Cancer Inst. 1998;90(1):43–9.CrossRef
3.
go back to reference Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121(3):621–32.CrossRef Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121(3):621–32.CrossRef
4.
go back to reference Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, et al. A review of human carcinogens--part B: biological agents. Lancet Oncol. 2009;10(4):321–2.CrossRef Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, et al. A review of human carcinogens--part B: biological agents. Lancet Oncol. 2009;10(4):321–2.CrossRef
5.
go back to reference Arbyn M, Raifu AO, Weiderpass E, Bray F, Anttila A. Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer. 2009;45(15):2640–8.CrossRef Arbyn M, Raifu AO, Weiderpass E, Bray F, Anttila A. Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer. 2009;45(15):2640–8.CrossRef
6.
go back to reference Gakidou E, Nordhagen S, Obermeyer Z. Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med. 2008;5(6):e132.CrossRef Gakidou E, Nordhagen S, Obermeyer Z. Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med. 2008;5(6):e132.CrossRef
7.
go back to reference de Ona M, Alvarez-Arguelles ME, Torrents M, Villa L, Rodriguez-Feijoo A, Palacio A, Boga JA, Tamargo A, Melon S. Prevalence, evolution, and features of infection with human papillomavirus: a 15-year longitudinal study of routine screening of a women population in the north of Spain. J Med Virol. 2010;82(4):597–604.CrossRef de Ona M, Alvarez-Arguelles ME, Torrents M, Villa L, Rodriguez-Feijoo A, Palacio A, Boga JA, Tamargo A, Melon S. Prevalence, evolution, and features of infection with human papillomavirus: a 15-year longitudinal study of routine screening of a women population in the north of Spain. J Med Virol. 2010;82(4):597–604.CrossRef
8.
go back to reference Leinonen MK, Anttila A, Malila N, Dillner J, Forslund O, Nieminen P. Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland. Br J Cancer. 2013;109(11):2941–50.CrossRef Leinonen MK, Anttila A, Malila N, Dillner J, Forslund O, Nieminen P. Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland. Br J Cancer. 2013;109(11):2941–50.CrossRef
9.
go back to reference Ley C, Bauer HM, Reingold A, Schiffman MH, Chambers JC, Tashiro CJ, Manos MM. Determinants of genital human papillomavirus infection in young women. J Natl Cancer Inst. 1991;83(14):997–1003.CrossRef Ley C, Bauer HM, Reingold A, Schiffman MH, Chambers JC, Tashiro CJ, Manos MM. Determinants of genital human papillomavirus infection in young women. J Natl Cancer Inst. 1991;83(14):997–1003.CrossRef
10.
go back to reference Schiffman M, Doorbar J, Wentzensen N, de Sanjose S, Fakhry C, Monk BJ, Stanley MA, Franceschi S. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016;2:16086.CrossRef Schiffman M, Doorbar J, Wentzensen N, de Sanjose S, Fakhry C, Monk BJ, Stanley MA, Franceschi S. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016;2:16086.CrossRef
11.
go back to reference Chen Q, Xie LX, Qing ZR, Li LJ, Luo ZY, Lin M, Zhang SM, Chen WZ, Lin BZ, Lin QL, et al. Epidemiologic characterization of human papillomavirus infection in rural Chaozhou, eastern Guangdong Province of China. PLoS One. 2012;7(2):e32149.CrossRef Chen Q, Xie LX, Qing ZR, Li LJ, Luo ZY, Lin M, Zhang SM, Chen WZ, Lin BZ, Lin QL, et al. Epidemiologic characterization of human papillomavirus infection in rural Chaozhou, eastern Guangdong Province of China. PLoS One. 2012;7(2):e32149.CrossRef
12.
go back to reference Syrjanen K. New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors. Eur J Gynaecol Oncol. 2008;29(3):205–21.PubMed Syrjanen K. New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors. Eur J Gynaecol Oncol. 2008;29(3):205–21.PubMed
13.
go back to reference Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlee F, Franco EL. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357(16):1579–88.CrossRef Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlee F, Franco EL. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357(16):1579–88.CrossRef
14.
go back to reference Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, Radberg T, Strander B, Johansson B, Forslund O, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357(16):1589–97.CrossRef Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, Radberg T, Strander B, Johansson B, Forslund O, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357(16):1589–97.CrossRef
15.
go back to reference Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, Kenter GG, Cuzick J, Snijders PJ, Meijer CJ. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13(1):78–88.CrossRef Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, Kenter GG, Cuzick J, Snijders PJ, Meijer CJ. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13(1):78–88.CrossRef
16.
go back to reference Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K. High-resolution profiling of histone methylations in the human genome. Cell. 2007;129(4):823–37.CrossRef Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K. High-resolution profiling of histone methylations in the human genome. Cell. 2007;129(4):823–37.CrossRef
17.
go back to reference Green RE, Krause J, Ptak SE, Briggs AW, Ronan MT, Simons JF, Du L, Egholm M, Rothberg JM, Paunovic M, et al. Analysis of one million base pairs of Neanderthal DNA. Nature. 2006;444(7117):330–6.CrossRef Green RE, Krause J, Ptak SE, Briggs AW, Ronan MT, Simons JF, Du L, Egholm M, Rothberg JM, Paunovic M, et al. Analysis of one million base pairs of Neanderthal DNA. Nature. 2006;444(7117):330–6.CrossRef
18.
go back to reference Fokom Domgue J, Schiffman M, Wentzensen NH, Gage JC, Castle PE, Raine-Bennett TR, Fetterman B, Lorey T, Poitras NE, Befano B, et al. Assessment of a new lower-cost real-time PCR assay for detection of high-risk human papillomavirus: useful for cervical screening in limited-resource settings? J Clin Microbiol. 2017;55(8):2348–55.CrossRef Fokom Domgue J, Schiffman M, Wentzensen NH, Gage JC, Castle PE, Raine-Bennett TR, Fetterman B, Lorey T, Poitras NE, Befano B, et al. Assessment of a new lower-cost real-time PCR assay for detection of high-risk human papillomavirus: useful for cervical screening in limited-resource settings? J Clin Microbiol. 2017;55(8):2348–55.CrossRef
19.
go back to reference Lou H, Villagran G, Boland JF, Im KM, Polo S, Zhou W, Odey U, Juarez-Torres E, Medina-Martinez I, Roman-Basaure E, et al. Genome analysis of Latin American cervical cancer: frequent activation of the PIK3CA pathway. Clin Cancer Res. 2015;21(23):5360–70.CrossRef Lou H, Villagran G, Boland JF, Im KM, Polo S, Zhou W, Odey U, Juarez-Torres E, Medina-Martinez I, Roman-Basaure E, et al. Genome analysis of Latin American cervical cancer: frequent activation of the PIK3CA pathway. Clin Cancer Res. 2015;21(23):5360–70.CrossRef
20.
go back to reference Castle PE, Sadorra M, Garcia FA, Cullen AP, Lorincz AT, Mitchell AL, Whitby D, Chuke R, Kornegay JR. Mouthwash as a low-cost and safe specimen transport medium for human papillomavirus DNA testing of cervicovaginal specimens. Cancer Epidemiol Biomark Prev. 2007;16(4):840–3.CrossRef Castle PE, Sadorra M, Garcia FA, Cullen AP, Lorincz AT, Mitchell AL, Whitby D, Chuke R, Kornegay JR. Mouthwash as a low-cost and safe specimen transport medium for human papillomavirus DNA testing of cervicovaginal specimens. Cancer Epidemiol Biomark Prev. 2007;16(4):840–3.CrossRef
21.
go back to reference Schmitt M, Dondog B, Waterboer T, Pawlita M. Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol. 2008;46(3):1050–9.CrossRef Schmitt M, Dondog B, Waterboer T, Pawlita M. Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol. 2008;46(3):1050–9.CrossRef
22.
go back to reference Snijders PJ, van den Brule AJ, Jacobs MV, Pol RP, Meijer CJ. HPV DNA detection and typing in cervical scrapes. Methods Mol Med. 2005;119:101–14.PubMed Snijders PJ, van den Brule AJ, Jacobs MV, Pol RP, Meijer CJ. HPV DNA detection and typing in cervical scrapes. Methods Mol Med. 2005;119:101–14.PubMed
23.
go back to reference Fokom Domgue J, Schiffman M, Wentzensen NH, Gage JC, Castle PE, Raine-Bennett TR, Fetterman B, Lorey T, Poitras NE, Befano B, et al. Assessment of a new lower-cost real-time PCR detection assay for high-risk HPV: useful for cervical screening in limited resource settings? J Clin Microbiol. 2017;55:2348.CrossRef Fokom Domgue J, Schiffman M, Wentzensen NH, Gage JC, Castle PE, Raine-Bennett TR, Fetterman B, Lorey T, Poitras NE, Befano B, et al. Assessment of a new lower-cost real-time PCR detection assay for high-risk HPV: useful for cervical screening in limited resource settings? J Clin Microbiol. 2017;55:2348.CrossRef
24.
go back to reference Nunez-Troconis J, Delgado M, Gonzalez J, Mindiola R, Velasquez J, Conde B, Whitby D, Munroe DJ. Prevalence and risk factors of human papillomavirus infection in asymptomatic women in a Venezuelan urban area. Investig Clin. 2009;50(2):203–12. Nunez-Troconis J, Delgado M, Gonzalez J, Mindiola R, Velasquez J, Conde B, Whitby D, Munroe DJ. Prevalence and risk factors of human papillomavirus infection in asymptomatic women in a Venezuelan urban area. Investig Clin. 2009;50(2):203–12.
25.
go back to reference Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, Balmaceda I, Greenberg MD, Alfaro M, Burk RD, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst. 2000;92(6):464–74.CrossRef Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, Balmaceda I, Greenberg MD, Alfaro M, Burk RD, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst. 2000;92(6):464–74.CrossRef
26.
go back to reference de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7(7):453–9.CrossRef de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7(7):453–9.CrossRef
27.
go back to reference Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE. Prevalence of HPV infection among females in the United States. JAMA. 2007;297(8):813–9.CrossRef Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE. Prevalence of HPV infection among females in the United States. JAMA. 2007;297(8):813–9.CrossRef
28.
go back to reference Alibegashvili T, Clifford GM, Vaccarella S, Baidoshvili A, Gogiashvili L, Tsagareli Z, Kureli I, Snijders PJ, Heideman DA, van Kemenade FJ, et al. Human papillomavirus infection in women with and without cervical cancer in Tbilisi, Georgia. Cancer Epidemiol. 2011;35(5):465–70.CrossRef Alibegashvili T, Clifford GM, Vaccarella S, Baidoshvili A, Gogiashvili L, Tsagareli Z, Kureli I, Snijders PJ, Heideman DA, van Kemenade FJ, et al. Human papillomavirus infection in women with and without cervical cancer in Tbilisi, Georgia. Cancer Epidemiol. 2011;35(5):465–70.CrossRef
29.
go back to reference Zhao R, Zhang WY, Wu MH, Zhang SW, Pan J, Zhu L, Zhang YP, Li H, Gu YS, Liu XZ. Human papillomavirus infection in Beijing, People's Republic of China: a population-based study. Br J Cancer. 2009;101(9):1635–40.CrossRef Zhao R, Zhang WY, Wu MH, Zhang SW, Pan J, Zhu L, Zhang YP, Li H, Gu YS, Liu XZ. Human papillomavirus infection in Beijing, People's Republic of China: a population-based study. Br J Cancer. 2009;101(9):1635–40.CrossRef
30.
go back to reference Guan P, Howell-Jones R, Li N, Bruni L, de Sanjose S, Franceschi S, Clifford GM. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012;131(10):2349–59.CrossRef Guan P, Howell-Jones R, Li N, Bruni L, de Sanjose S, Franceschi S, Clifford GM. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012;131(10):2349–59.CrossRef
31.
go back to reference Lo KW, Wong YF, Chan MK, Li JC, Poon JS, Wang VW, Zhu SN, Zhang TM, He ZG, Wu QL, et al. Prevalence of human papillomavirus in cervical cancer: a multicenter study in China. Int J Cancer. 2002;100(3):327–31.CrossRef Lo KW, Wong YF, Chan MK, Li JC, Poon JS, Wang VW, Zhu SN, Zhang TM, He ZG, Wu QL, et al. Prevalence of human papillomavirus in cervical cancer: a multicenter study in China. Int J Cancer. 2002;100(3):327–31.CrossRef
32.
go back to reference Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. J Natl Cancer Inst. 1995;87(11):796–802.CrossRef Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. J Natl Cancer Inst. 1995;87(11):796–802.CrossRef
33.
go back to reference Haguenoer K, Giraudeau B, Gaudy-Graffin C, de Pinieux I, Dubois F, Trignol-Viguier N, Viguier J, Marret H, Goudeau A. Accuracy of dry vaginal self-sampling for detecting high-risk human papillomavirus infection in cervical cancer screening: a cross-sectional study. Gynecol Oncol. 2014;134(2):302–8.CrossRef Haguenoer K, Giraudeau B, Gaudy-Graffin C, de Pinieux I, Dubois F, Trignol-Viguier N, Viguier J, Marret H, Goudeau A. Accuracy of dry vaginal self-sampling for detecting high-risk human papillomavirus infection in cervical cancer screening: a cross-sectional study. Gynecol Oncol. 2014;134(2):302–8.CrossRef
34.
go back to reference Trope LA, Chumworathayi B, Blumenthal PD. Preventing cervical cancer: stakeholder attitudes toward CareHPV-focused screening programs in Roi-et Province, Thailand. Int J Gynecol Cancer. 2009;19(8):1432–8.CrossRef Trope LA, Chumworathayi B, Blumenthal PD. Preventing cervical cancer: stakeholder attitudes toward CareHPV-focused screening programs in Roi-et Province, Thailand. Int J Gynecol Cancer. 2009;19(8):1432–8.CrossRef
36.
go back to reference Jeronimo J, Holme F, Slavkovsky R, Camel C. Implementation of HPV testing in Latin America. J Clin Virol. 2016;76(Suppl 1):S69–73.CrossRef Jeronimo J, Holme F, Slavkovsky R, Camel C. Implementation of HPV testing in Latin America. J Clin Virol. 2016;76(Suppl 1):S69–73.CrossRef
37.
go back to reference Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011;103(5):368–83.CrossRef Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011;103(5):368–83.CrossRef
Metadata
Title
Low-cost HPV testing and the prevalence of cervical infection in asymptomatic populations in Guatemala
Authors
Hong Lou
Eduardo Gharzouzi
Sarita Polo Guerra
Joël Fokom Domgue
Julie Sawitzke
Guillermo Villagran
Lisa Garland
Joseph F. Boland
Sarah Wagner
Héctor Rosas
Jami Troxler
Heidi McMillen
Bailey Kessing
Enrique Alvirez
Miriam Castillo
Hesler Morales
Victor Argueta
Andert Rosingh
Femke J. H. B. van Aerde-van Nunen
Griselda Lopez
Herbert M. Pinedo
Mark Schiffman
Michael Dean
Roberto Orozco
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4438-y

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine